Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Soleus sold 474,000 before the end of March

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on May 18, 2021 4:15pm

111 Views

Post# 33223923

RE:RE:RE:Soleus sold 474,000 before the end of March

I really believe the key to deal with the valuation discrepancies is addinh a retail friendly approach to their marketing efforts.
Get the demand and volume higher first then institutional investors and wealthy retail investors will join the party.

SPCEO1 wrote: There is no indication of other new institutional owners so one has to wonder if the other two purported institutions who participated in the OO have flipped their shares already. That seems unlikely, but no other group with more than 1% of the outstanding shares are listed on Bloomberg besides Soleus, ourselves and the Caisse.

scarlet1967 wrote: As per their 13F yesterday filing Worth Venture partners increased their position from 146162 to 851413 shares and Morgan Stanley increased their position from 403870 shares to 703735 shares.

https://fintel.io/sob/us/thtx

SPCEO1 wrote: They still own nearly 7 million shares as of the end of March but did sell 474,000 between the offering and the end of March. Not sure what, if anything, that might mean but that is what Bloomberg is reporting.